Furthermore, the optimal timing of treatment initiation could depend on the underlying cluster pattern, as tau positivity in conventional estimation methods may be affected by distinguishable spreading patterns especially in preclinical AD. The gene discussed is MAPT; the disease is Alzheimer disease.